$ONPH News
Last published 4y ago
- 4y agoONPHOncology Pharma Releases Further Feasibility Studies, Data and CapacitiesACCESS NewswireSAN FRANCISCO, CA / ACCESSWIRE / February 23, 2022 / Oncology Pharma Inc. (OTC:ONPH) - Oncology Pharma, Inc. ("The Company") looks toward releasing further results of the studies under the Co-Development Agreement with NanoSmart Pharmaceuticals, demonstr
- 4y agoONPHOncology Pharma Expands on Feasibility Studies and DataACCESS NewswireSAN FRANCISCO, CA / ACCESSWIRE / February 17, 2022 / Oncology Pharma Inc. (OTC:ONPH) - Oncology Pharma, Inc. ("The Company") wants to expand on a previously announced press release that included results of formulations and data on licensed technology wit
- 4y agoONPHRGBPRGBPPOncology Pharma, Inc. and Regen BioPharma, Inc. Announce Intent to Jointly Fast Track Development of Modified mRNA anti-Cancer VaccineACCESS NewswireSAN FRANCISCO, CA / ACCESSWIRE / February 14, 2022 / Oncology Pharma, Inc. ("The Company") (OTC:ONPH) and Regen BioPharma, Inc. (OTC:RGBP) and (OTC:RGBPP): announced that they intend to work jointly to fast track the development of therapeutic uses relat
- 4y agoONPHOncology Pharma Gives Update on Technology, Formulation and Data CreationACCESS NewswireSAN FRANCISCO, CA / ACCESSWIRE / February 8, 2022 / Oncology Pharma Inc. (OTC:ONPH) - Oncology Pharma, Inc. ("The Company") is pleased to announce that the co-development agreement and ongoing work to advance the licensed technology with Nanosmart has id
- 4y agoONPHOncology Pharma's New Year UpdateACCESS NewswireSAN FRANCISCO, CA / ACCESSWIRE / January 10, 2022 / Oncology Pharma Inc. (OTC:ONPH) - Oncology Pharma, Inc. ("The Company") update on its progress to kick off the new year. The Company has advanced its relationship and made further investment into Ribei
- 4y agoONPHOncology Pharma Meeting Towards Future DevelopmentsACCESS NewswireSAN FRANCISCO, CA / ACCESSWIRE / December 17, 2021 / Oncology Pharma Inc. (OTC:ONPH) Oncology Pharma, Inc. ("The Company") conducted a meeting with the Board of Directors, executives, and Scientific Advisory Board members along with legal counsel, which
- 4y agoONPHOncology Pharma Year End Review and OutlookACCESS NewswireSAN FRANCISCO, CA / ACCESSWIRE / December 9, 2021 / Oncology Pharma Inc. (OTC:ONPH) - Oncology Pharma, Inc. ("The Company") and its Chief Executive are pleased to give a year end update and provide an outlook for what to look for in the coming months and
- 4y agoONPHOncology Pharma Research and VisionACCESS NewswireSAN FRANCISCO, CA / ACCESSWIRE / November 30, 2021 / Oncology Pharma Inc. (OTC:ONPH) - Oncology Pharma, Inc. ("The Company") is a pioneering oncology company dedicated to providing the financing and the tools to license, develop, manufacture, and commerc
- 5y agoONPHOncology Pharma Reveals Plans for Development of Lead Cancer Drug CandidateACCESS NewswireSAN FRANCISCO, CA / ACCESSWIRE / November 8, 2021 / Oncology Pharma, Inc. (the "Company") is pleased to provide some insight into the progress of its co-development project with NanoSmart Pharmaceuticals, Inc. for the development of a lead cancer drug ca
- 5y agoONPHOncology Pharma, Inc. Gives Update on Ongoing Work and ProgressACCESS NewswireSAN FRANCISCO, CA / ACCESSWIRE / October 27, 2021 / Oncology Pharma Inc. (OTC:ONPH) Pursuant to previous communications, Oncology Pharma, Inc. (the "Company") is making progress towards pursuing its primary goal of the Co-Development plan to bring new ph
- 5y agoONPHOncology Pharma, Inc. Has Engaged a PCAOB Audit Firm Looking Towards Moving the Company Towards a Senior ListingACCESS NewswireSAN FRANCISCO, CA / ACCESSWIRE / October 15, 2021 / Oncology Pharma Inc. (OTC:ONPH) Pursuant to previously announced press release, Oncology Pharma, Inc. (the "Company") has retained the services of DBBMcKennon, LLC, a PCAOB Certified Public Accounting F
- 5y agoONPHOncology Pharma, Inc. Update on PCAOB Audit Selection Process and License AgreementACCESS NewswireSAN FRANCISCO, CA / ACCESSWIRE / October 12, 2021 / Oncology Pharma Inc. (OTC:ONPH) Oncology Pharma, Inc. (the "Company") would like to update investors on its progress. The Company is in the final stages of engaging with a PCAOB Audit firm to support it
- 5y agoONPHOncology Pharma, Inc. Has Received the Committed Funding to Perform All Necessary IND-Enabling Preclinical Work for Its First Lead Candidate, a Dactinomycin Nanoemulsion Drug ProductACCESS NewswireSAN FRANCISCO, CA / ACCESSWIRE / September 13, 2021 / Oncology Pharma, Inc. (OTC:ONPH). In keeping with management's commitment to continue implementation of Oncology Pharma's ("the Company") capital formation plan, the Company has obtained, received and
- 5y agoONPHOncology Pharma's Co-Development Agreement Pursues Strategic and Direct ObjectivesACCESS NewswireSAN FRANCISCO, CA / ACCESSWIRE / August 23, 2021 / Oncology Pharma, Inc. (OTC:ONPH) defines its objective and strategy for recently signed Co-Development deal. The primary goal of the Co-Development plan is to bring new pharmaceutical drug formulations t
- 5y agoONPHOncology Pharma, Inc. Executes Co-Development Agreement with NanoSmart Pharmaceuticals, Inc.ACCESS NewswireSAN FRANCISCO, CA / ACCESSWIRE / August 19, 2021 / Oncology Pharma Inc. (OTC:ONPH) With much anticipation, Oncology Pharma, Inc. has finalized a Co-Development Agreement with NanoSmart Pharmaceuticals, Inc. Oncology Pharma will pursue the early feasibili
- 5y agoONPHOncology Pharma, Inc. To Move to Conducting Trials on Licensed IPACCESS NewswireSAN FRANCISCO, CA / ACCESSWIRE / July 20, 2021 / Oncology Pharma Inc. (OTC:ONPH) Oncology Pharma, Inc. (the "Company") is laying out and taking necessary steps to move its licensed IP forward. From obtaining the necessary financing, in order to support s
- 5y agoONPHOncology Pharma, Inc. is Entering Into the Next Phase of its Growth and Expansion PhaseACCESS NewswireSAN FRANCISCO, CA / ACCESSWIRE / June 30, 2021 / Oncology Pharma Inc. (OTC:ONPH) Oncology Pharma, Inc. (the "Company") is developing a program to establish the use of its license utilizing NR2F6 agonists and antagonists coupled with the proprietary drug
- 5y agoONPHOncology Pharma, Inc. Eyes Collaboration with Patent Opportunities Amongst Its Licensed Intellectual PropertiesACCESS NewswireSAN FRANCOSCO, CA / ACCESSWIRE / June 15, 2021 / Oncology Pharma Inc. (OTC:ONPH) Oncology Pharma, Inc. (the 'Company') has been continuing its research and work reviewing and implementing collaboration between its interests in therapy, delivery and trial
- 5y agoONPHOncology Pharma and Ribera Solutions Release White Paper Regarding Patient Engagement and Retention PlatformACCESS NewswireSAN FRANCISCO, CA / ACCESSWIRE / June 9, 2021 / Oncology Pharma Inc. (OTC:ONPH) Oncology Pharma, Inc. (the 'Company') is releasing a White Paper outlining 5 innovative ways to improve patient engagement in clinical trials. The five key points in the Whit
- 5y agoONPHOncology Pharma, Inc. Is Pursuing the Development of Its Small Molecule Drug for the Treatment of Colon CancerACCESS NewswireSAN FRANCISCO, CA / ACCESSWIRE / May 18, 2021 / Oncology Pharma Inc. (OTC:ONPH) Oncology Pharma, Inc. (the "Company") is pursuing, through its licensing arrangements, the development of a small molecule drug ("SMD") for the treatment of colon cancer. SMD
- 5y agoONPHOncology Pharma, Inc. Has Submitted Its Initial Application to List the Company on the Capital Markets Tier of the NASDAQ ExchangeACCESS NewswireSAN FRANCISCO, CA / ACCESSWIRE / May 12, 2021 / Oncology Pharma Inc. (OTC:ONPH) Oncology Pharma, Inc. (the "Company") has submitted its initial application to the NASDAQ to begin the process of moving the listing from the Pink Sheets to the Capital Marke
- 5y agoONPHOncology Pharma Enters into License Agreement for Small Molecules Intellectual Property for the Treatment of Colon CancerACCESS NewswireSAN FRANCISCO, CA / ACCESSWIRE / May 7, 2021 / Oncology Pharma Inc. (OTC:ONPH) ONPH has entered into a licensing agreement with Regen BioPharma, Inc. for a technology utilizing small molecules to activate immune checkpoints for the treatment of colon can